

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

WO 99/51198

(51) International Patent Classification 6 : A61K 7/42, 7/06, 7/00, 31/19, 31/045, 31/07	A1	(11) International Publication Number: WO 99/51198
		(43) International Publication Date: 14 October 1999 (14.10.99)

(21) International Application Number: **PCT/US99/07495**
(22) International Filing Date: **6 April 1999 (06.04.99)**

(30) Priority Data: **09/055,274** **6 April 1998 (06.04.98)** **US**

(71) Applicant (for all designated States except US): **CODON PHARMACEUTICALS, INC. [US/US]; 200 Perry Parkway, Gaithersburg, MD 20877 (US).**

(72) Inventors; and
(75) Inventors/Applicants (for US only): **REN, Wu, Yun [US/US]; 12518 Timber Hollow Place, Germantown, MD 20874 (US). SEIDMAN, Michael [US/US]; 3639 Veazey Street, N.W., Washington, DC 20008 (US). BROWN, David, A. [US/US]; 4534 Kingcup Court, Ellicott City, MD 21042 (US).**

(74) Agent: **TARCZA, John, E.; Codon Pharmaceuticals, Inc., 200 Perry Parkway, Gaithersburg, MD 20877 (US).**

(81) Designated States: **AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, LC, LK, LR, LS, LT, LV, MG, MK, MN, MW, MX, NO, NZ, PL, RO, SD, SG, SI, SK, SL, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Published
With international search report.

(54) Title: **DERMATOLOGICAL FORMULATIONS AND METHODS**

(57) Abstract

A method and dermatological formulation are provided for increasing the pigmentation response of mammalian skin, hair, wool or fur to agents which stimulate melanogenesis. The method comprises administering to mammalian skin, hair, wool or fur a dermatological formulation containing a melanogenesis-stimulating effective amount of an agent which stimulates melanogenesis in melanocytes, and a melanogenesis-enhancing effective amount of an agent, such as an α -hydroxy acid, which enhances the stimulation of melanogenesis by the melanogenesis-stimulation agent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

DERMATOLOGICAL FORMULATIONS AND METHODS

BACKGROUND OF THE INVENTION5 1. Field of the Invention

The present invention relates to enhancing the pigmentation response to inducers of melanogenesis by inclusion of melanogenesis-enhancing agents in formulations applied to skin, hair, wool or fur.

2. Description of the Related Art

There have been various descriptions of the use of compounds for stimulating melanogenesis or pigmentation. U.S. Patent No. 5,352,440 describes increasing melanin synthesis in melanocytes and increasing pigmentation by administration of certain diacylglycerol compounds.

Increased pigmentation in mammalian skin via administration of certain DNA fragments is disclosed in U.S. Patent No. 5,532,001. U.S. Patent No. 5,554,359 is directed to increasing levels of melanin in melanocytes by administration of lysosomotropic agents. And various melanogenic diols are described in Brown et al., 1998, J.

Invest. Dermatol., 110:428-427.

While certain methods and compositions for stimulating pigmentation are known, there exists a need for improvements in the art. The present invention provides improved methods and compositions for stimulating pigmentation responses in mammalian skin, hair, wool or fur.

SUMMARY OF THE INVENTION

The present invention provides a method for increasing the pigmentation response of mammalian skin, hair, wool or fur to agents which stimulate melanogenesis, comprising
5 administering to mammalian skin, hair, wool or fur a dermatological formulation comprising a melanogenesis-stimulating effective amount of an agent which stimulates melanogenesis in melanocytes, and a melanogenesis-enhancing effective amount of an agent which enhances the stimulation
10 of melanogenesis by the melanogenesis-stimulating agent. More particularly, the melanogenesis-enhancing compounds are selected from among α -hydroxy acids, salts and derivatives thereof; α -keto acids, salts and derivatives thereof; β -hydroxy acids, salts and derivatives thereof; retinoids,
15 salts and derivatives thereof; Vitamin A and related compounds; acids such as trichloroacetic acid and trifluoroacetic acid; phenol; and, methoxypropyl-gluconamide.

Another aspect of the present invention provides a
20 dermatological formulation for increasing the pigmentation response of mammalian skin, hair, wool or fur to agents which stimulate melanogenesis. The formulation comprises a melanogenesis-stimulating effective amount of an agent which stimulates melanogenesis in melanocytes, and a
25 melanogenesis-enhancing effective amount of an agent which enhances the stimulation of melanogenesis by the melanogenesis-stimulating agent. More particularly, the melanogenesis-enhancing compounds are selected from among α -

hydroxy acids, salts and derivatives thereof; α -keto acids, salts and derivatives thereof; β -hydroxy acids, salts and derivatives thereof; retinoids, salts and derivatives thereof; Vitamin A and related compounds; acids such as trichloroacetic acid and trifluoroacetic acid; phenol; and, methoxypropyl-gluconamide.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1B illustrate skin pigmentation responses.

10

DESCRIPTION OF THE PREFERRED EMBODIMENTS

This invention is based on the unique observation that certain compounds greatly increase the pigmentation response in mammalian skin treated with agents known to stimulate melanin production in melanocytes. Thus, the present invention is useful in the treatment of hypopigmentation disorders, such as albinism, vitiligo, etc. It is also believed that increasing the pigmentation of skin according to the present invention will protect such skin from subsequent UV light damage, sunburn, photoaging and development of skin cancers.

The present invention may be used in the treatment of any mammalian skin, hair, wool or fur. Treatment of human skin is preferred.

As discussed above, the present invention provides for an increased pigmentation response by administration of a composition comprising (1) an agent which stimulates melanin

production in melanocytes (i.e., a melanogenesis-stimulating agent), and (2) a compound which enhances pigmentation by the melanogenesis-stimulating agent (i.e., a melanogenesis-enhancing agent). The melanogenesis-enhancing agent serves
5 to provide a greater pigmentation response to a melanogenesis-stimulating agent than would otherwise occur.

Melanogenesis-stimulating agents according to the present invention include melanogenic diols, triols and alcohols including but not limited to derivatives of
10 norbornane, pinane and camphane; 3-isobutyl-1-methylxanthine 1,3-disubstituted xanthine, theophylline and its analogs and derivatives; diacylglycerol and its analogs including but not limited to 1-oleoyl-2-acetyl-glycerol, 1-oleoyl-2-butanoyl-glycerol, 1,2-diacetyl-glycerol, 1,2-butanoyl-
15 glycerol, and 1-hexanoyl-2-oleoyl-glycerol; lysosomotropic agents; and DNA fragments. Any melanogenesis-stimulating agent may be used as long as its ability to stimulate melanogenesis is increased by the melanogenesis-enhancing agent.

20 Preferred melanogenesis-stimulating agents are the melanogenic diols, triols and alcohols as described in U.S. Application Serial No. 08/933,143, filed September 18, 1997, and PCT/US98/_____ entitled "Pharmaceutical Compositions and Methods", filed March 18, 1998, the
25 contents of which are hereby incorporated by reference. Especially preferred melanogenic diols, triols and alcohols for use according to the present invention include 2,3-cis/exo-pinenediol ([1R,2R,3S,5R]-[-]-pinenediol and

[1S,2S,3R,5S] - [+] -pinanediol); 2,3-cis/exo-bornanediol; 5-norbornene-2,2-dimethanol; norbornane-2,2-dimethanol; 2-hydroxy-2-norbornanemethanol; 1-(exo-2-norbornyl-) -propan-1,2-diol; and, 1-(endo-2-norbornyl-) -propan-1,2-diol.

5 Melanogenesis-enhancing agents according to the present invention include α -hydroxy acids, salts and derivatives thereof such as glycolic acid, lactic acid, ammonium lactate, mandelic acid, benzilic acid, malic acid, tartaric acid, gluconic acid and citric acid; α -keto acids, salts and
10 derivatives thereof such as pyruvic acid; β -hydroxy acids, salts and derivatives thereof such as salicylic acid; retinoids, salts and derivatives thereof such as tretinoin and isotretinoin; Vitamin A, Vitamin A₂ and Vitamin A aldehyde; acids such as trichloroacetic acid and
15 trifluoroacetic acid; phenol; and, methoxypropyl-gluconamide. The aforementioned compounds possess properties such as the ability to diminish epidermal corneocyte cohesion, reduce stratum corneum thickness, stimulate keratinocyte proliferation, increase epidermal
20 thickness, result in more even distribution of melanocytes, result in more even distribution of melanin, and to stimulate dispersal of melanin. Any melanogenesis-enhancing agent may be used as long as it enhances the ability of a melanogenesis-stimulating agent to increase melanin
25 production by melanocytes. Alpha-hydroxy acids are the preferred melanogenesis-enhancing agent.

Alpha-hydroxy acids have not been reported to possess melanogenic ability. In fact, α -hydroxy acids have been

used to reduce hyperpigmentation of photoaged skin (Van Scott, E.J., and Yu, R.J., 1989, *Cutis* 43:222-228; Stiller et al., 1996, *Arch. Dermatol.* 132:631-636). The present inventors, however, suggest that the effects of α -hydroxy acids which reduce pigmentation of photoaged skin are likely to be the same effects which increase the pigmentation response to agents that stimulate melanogenesis in melanocytes. Specifically, α -hydroxy acids have been reported to result in "more even distribution of melanocytes and melanin pigment" (Gilchrest, B.A., 1996, *Br. J. Dermatol.* 135:867-875), "less clumping of melanin pigmentation with α -hydroxy acid treatment" and "dispersal of melanin pigmentation" (Ditre, C.M. et al., 1996, *J. Am. Acad. Dermatol.* 34:187-195). In addition, α -hydroxy acid treatment results in increased proliferation and turnover of keratinocytes, which increases the rate of transport of melanin to the surface layers of the skin where it is sloughed off. In the absence of stimulation of melanogenic activity, the net result is an accelerated rate of loss of pigmentation. However, by the present invention it is contemplated that when α -hydroxy acids, or melanogenesis-enhancing agents in general, are applied to skin with a melanogenesis-stimulating agent, the α -hydroxy acids (or melanogenesis-enhancing agents) assist the processes of melanogenesis by enhancing distribution of melanin through the epidermis.

The natural tanning response as elicited by solar irradiation stimulates not only melanin production in

melanocytes, but also proliferation of keratinocytes such that transport of melanin through the epidermis is enhanced (Jimbow, K., et al., 1991. Biochemistry and physiology of melanin production, pages 873-909, In: Physiology, Biochemistry, and Molecular Biology of the Skin, L. A. Goldsmith, ed. Oxford University Press, New York, USA.; Jimbow, K., et al., 1993. Biology of melanocytes, pages 261-289, In: Dermatology in General Medicine, Volume 1, Fourth Edition, T.B. Fitzpatrick et al., ed. McGraw-Hill, Inc., New York). Melanogenic diols act directly on melanocytes to stimulate melanogenesis (Brown et al., 1997, J. Invest. Dermatol., In Press), but there is no evidence to indicate that melanogenic diols stimulate proliferation of human keratinocytes. Thus, they may stimulate only part of the physiological response necessary for effective tanning.

It is contemplated that melanogenesis-enhancing agents, e.g., α -hydroxy acids, complete the requirements for effective tanning by stimulating the proliferation of keratinocytes and thereby facilitating the distribution of melanin throughout the epidermis. Furthermore, the reduced clumping of melanin and increased dispersal of melanin which are enhanced by α -hydroxy acids are well-known features of darkly pigmented skin (Jimbow, K., et al., 1993. Biology of melanocytes, pages 261-289, In: Dermatology in General Medicine, Volume 1, Fourth Edition, T. B. Fitzpatrick et al., ed. McGraw-Hill, Inc., New York).

It is further contemplated that all agents which are presently used for repair of photoaging and/or stimulation

WO 99/51198

of epidermal turnover (skin refreshing or peeling) will be effective as melanogenesis-enhancing agents in facilitating the pigmentation response induced by melanogenesis-stimulating agents.

5 The methods and compositions of the present invention contemplate the use of one or more melanogenesis-stimulating agents as an active ingredient to stimulate melanogenesis, and one or more melanogenesis-enhancing agents to enhance pigmentation. In a preferred embodiment, the active
10 ingredients are combined with an acceptable carrier to form a topical formulation which may be placed on the skin. Topical formulations may include ointments, lotions, pastes, creams, gels, drops, suppositories, sprays, liquids, shampoos, powders and transdermal patches. Thickeners,
15 diluents, emulsifiers, dispersing aids or binders may be used as needed. Preferably, one function of the carrier is to enhance skin penetration of the active ingredients, and should be capable of delivering the active ingredients to melanocytes under in vivo conditions. Suitable carriers are
20 well known to one of ordinary skill, and include liposomes, ethanol, dimethylsulfoxide (DMSO), petroleum jelly (petrolatum), mineral oil (liquid petrolatum), water, dimethylformamide, dekaoxyethylene-oleylether, oleic acid, 2-pyrrolidone and Azone® brand penetration enhancer
25 (Upjohn). Depending on the specific application, the compositions of the present invention may also include other active ingredients, as well as inert or inactive ingredients.

The dose regimen will depend on a number of factors which may readily be determined, such as severity and responsiveness of the condition to be treated, but will normally be one or more doses per day, with a course of treatment lasting from several days to several months, or until a cure is effected or a diminution of disease state is achieved, or a cosmetically desired degree of melanogenesis (tanning) is achieved, depending on the application. One of ordinary skill may readily determine optimum dosages, dosing methodologies and repetition rates. In general, it is contemplated that topical formulations (such as creams, lotions, solutions, etc.) will have a concentration of melanogenesis-stimulating agent of from about 0.01% to about 50%, preferably from about 0.1% to about 10%.

It is contemplated that melanogenesis-enhancing agents will be used at concentrations which diminish epidermal corneocyte cohesion, reduce stratum corneum thickness, stimulate keratinocyte proliferation, and increase epidermal thickness, without resulting in the phenomena known as "chemical peeling" (Piacquadio, D., et al., 1996, Dermatol. Surg. 22:449-452). As such, the effective concentrations of melanogenesis-enhancing agents are expected to be in the range of 5% to 25% by weight (Stiller et al., 1996, Arch. Dermatol. 132:631-636; Ditre et al., 1996, J. Am. Acad. Dermatol. 34:187-195). However, in some cases where reparation of photodamaged skin is desirable prior to induction of pigmentation (tanning), it is contemplated that much higher concentrations of melanogenesis-enhancing agents

WO 99/51198

may be used. Additionally, it is contemplated that short-term higher concentrations of melanogenesis-enhancing agents may be used instead of longer term application of lower concentrations of melanogenesis-enhancing agents.

5 The use of and useful and novel features of the present methods and compositions will be further understood in view of the following non-limiting examples.

Example 1

10 The melanogenic agent 2,3-R-pinenediol (2,3-R-PD) was formulated with inclusion of an α -hydroxy acid cream as follows:

	70% Isopropyl <u>Alcohol*</u>	2,3-R-Pin- <u>enediol</u>	α -Hydroxy <u>Acid Cream**</u>	1,2-Propylene <u>Glycol</u>
15				
	#1 165 μ l	85 mg	250 μ l	
	#2	85 mg	250 μ l	165 μ l

20 *70% Isopropyl Rubbing Alcohol (CVS)
 **Alpha Hydroxy Face Cream (CVS) which contains 8% active
 alpha hydroxy acids

25

10 μ l of each solution was applied 3 times per day to the skin of a human subject. Solution #1 was applied for 6 days, while solution #2 was applied for 3 days. Solution #1 resulted in no irritation or erythema during the 6 day application period, while solution #2 resulted in irritation and erythema on the third day of application. Treated spots were subjectively evaluated for pigmentation response using a subjective rating system as follows: 0 = no change from

30

background; +0.25 = slight darkening, indistinct; +0.5 = slight darkening, distinct; +1 = slight-moderate darkening; +2 moderate, even darkening; +3 = substantial, even darkening; +4 = profound, even darkening.

5 When evaluated for pigmentation response 5 days after the cessation of applications, the location where Solution #1 was applied (Figure 1 A) exhibited moderate even darkening (pigmentation rating =2), while the spot where Solution #2 was applied (Figure I B) exhibited slight to
10 moderate darkening (pigmentation rating = 1). In a previous experiment in which 10 μ l 2,3-R-pinenediol dissolved in 100% ethanol was applied to the same subject 3-8 times per day for 6 days, the maximum pigmentation response obtained was slight darkening (pigmentation rating =0.5). These findings
15 show that inclusion of α -hydroxy acid in formulations results in 4-fold enhancement of the pigmentation response induced by 2,3-R-pinenediol.

Pigmentation of the location where Solution #1 was applied became apparent approximately 2 days after the final
20 day of application. Pigmentation response where Solution #1 was applied exhibited the following temporal pattern of pigmentation:

	<u>Days After Cessation of Solution #1 Application</u>	<u>Pigmentation Response*</u>
	2	0.5
5	3	1
	4	1.5
	5	2
	6	2.5
	7	2
10	9	1.5
	12	1
	13	0.5
	15	0.25

15 *Subjective rating scale where: 0 = no change from
background; +0.25 = slight darkening, indistinct; +0.5 =
slight darkening, distinct; +1 = slight-moderate darkening;
+2 = moderate, even darkening; +3 = substantial, even
darkening; +4 = profound, even darkening.

20

Alpha-hydroxy acids do not induce melanogenesis.
However, α -hydroxy acids are known to diminish epidermal
25 corneocyte cohesion, reduce stratum corneum thickness,
stimulate keratinocyte proliferation, increase epidermal
thickness, result in more even distribution of melanocytes,
result in more even distribution of melanin, and stimulate
dispersal of melanin. Therefore, it is contemplated that
30 α -hydroxy acids facilitate melanogenesis induced by 2,3-R-
pinanediol by diminishing clumping of melanin, by
stimulating dispersal of melanin including passage into
keratinocytes, and by accelerating transport of melanin
through the epidermis by stimulating proliferation of
35 keratinocytes.

There are no reports of α -hydroxy face cream or
ingredients therein stimulating melanogenesis. Thus, it
contemplated that it is the unique combination of agents
which stimulate melanin production in melanocytes (e.g,

melanogenic diols), and α -hydroxy acids which stimulate proliferation of keratinocytes with resultant melanin mobilization, that results in marked induction of skin pigmentation or sunless tanning. Further, it is contemplated that this combination of stimulation of melanin production in melanocytes, and stimulation of keratinocyte proliferation in epidermis, parallels the major physiological responses involved in the natural tanning process induced by solar irradiation.

10

We claim:

1. A method for increasing the pigmentation response of mammalian skin, hair, wool or fur to agents which stimulate melanogenesis, comprising administering to mammalian skin, hair, wool or fur a dermatological formulation comprising a melanogenesis-stimulating effective amount of an agent which stimulates melanogenesis in melanocytes, and a melanogenesis-enhancing effective amount of an agent which enhances the stimulation of melanogenesis by the melanogenesis-stimulating agent.

2. The method according to claim 1, wherein the melanogenesis-enhancing agent is selected from the group consisting of α -hydroxy acids, salts and derivatives thereof; α -keto acids, salts and derivatives thereof; β -hydroxy acids, salts and derivatives thereof; retinoids, salts and derivatives thereof; Vitamin A and related compounds; acids; phenol; and, methoxypropyl-gluconamide.

3. The method according to claim 1, wherein the melanogenesis-enhancing agent comprises α -hydroxy acids.

4. The method according to claim 3, wherein the α -hydroxy acid is selected from the group consisting of glycolic acid, lactic acid, ammonium lactate, mandelic acid, benzilic acid, malic acid, tartaric acid, gluconic acid and citric acid.

5. The method according to claim 1, wherein the dermatological formulation is administered to human skin.

6. The method according to claim 1, wherein the
5 melanogenesis-stimulation agent comprises 2,3-R-pinanediol.

7. A dermatological formulation for increasing the pigmentation response of mammalian skin, hair, wool or fur to agents which stimulate melanogenesis, comprising a
10 melanogenesis-stimulating effective amount of an agent which stimulates melanogenesis in melanocytes, and a melanogenesis-enhancing effective amount of an agent which enhances the stimulation of melanogenesis by the melanogenesis-stimulating agent.

15

8. The formulation according to claim 7, wherein the melanogenesis-enhancing agent is selected from the group consisting of α -hydroxy acids, salts and derivatives thereof; α -keto acids, salts and derivatives thereof; β -
20 hydroxy acids, salts and derivatives thereof; retinoids, salts and derivatives thereof; Vitamin A and related compounds; acids; phenol; and, methoxypropyl-gluconamide.

9. The formulation according to claim 7, wherein the
25 melanogenesis-enhancing agent comprises α -hydroxy acids.

10. The formulation according to claim 9, wherein the α -hydroxy acid is selected from the group consisting of

glycolic acid, lactic acid, ammonium lactate, mandelic acid, benzilic acid, malic acid, tartaric acid, gluconic acid and citric acid.

- 5 11. The method according to claim 7, wherein the melanogenesis-stimulation agent comprises 2,3-R-pinanediol.




Figure 1

Best Available Copy

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/07495

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 7/42, 7/06, 7/00, 31/19, 31/045, 31/07
US CL : 424/59, 70.1, 70.6, 70.9, 401; 514/557, 724, 725, 728
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/59, 70.1, 70.6, 70.9, 401; 514/557, 724, 725, 728

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN
search terms: melanogenesis, melanocyte, pigmentation, pinanediol

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- A	US 5,698,184 A (PICKART) 16 December 1997, col. 12, lines 19-23; col. 8, lines 1-16; col. 9, lines 30-37; Abstract. Abstract	1-5, 7-10 ---- 6, 11

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
19 MAY 1999

Date of mailing of the international search report
01 JUN 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer

MARINA LAMM

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*